Related Experiment Video
Updated: May 5, 2026

Single-Cell Optical Action Potential Measurement in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: December 22, 2020
A call for transparency, improved reporting, and interpretation of trials using surrogate end points in cardiac
Larisa G Tereshchenko1, Anthony Muchai Manyara2, Oriana Ciani3
1Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.
Abstract:
In this call for transparency, we aim to disseminate knowledge about recent CONSORT-Surrogate and SPIRIT-Surrogate checklists. SPIRIT-Surrogate is an extension of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist, developed as a consensus document and designed as a reporting guideline for randomized controlled trial (RCT) protocols using surrogate end points as the primary end points. CONSORT-Surrogate is an extension of the Consolidated Standards of Reporting Trials (CONSORT) checklist, a consensus-driven reporting guideline for RCTs using surrogate end points as the primary end points. We discuss the definition of surrogate and target/final end points in cardiac electrophysiology (EP) RCTs. We review historical examples of surrogate paradoxes in the cardiac EP field and consider the theoretical framework of a surrogate paradox. Furthermore, we consider the bioethics of transparent reporting of clinical trial protocols and results. A nonlethal cardiac arrhythmia and its burden (eg, atrial fibrillation, premature ventricular contractions, nonsustained ventricular tachycardia) is a surrogate end point unless justified otherwise. Therefore, clinical investigators in the cardiac EP field need to implement the SPIRIT-Surrogate and CONSORT-Surrogate extension checklists for transparent reporting.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

